Literature DB >> 7573295

Benefits and risks of estrogen replacement therapy.

R A Lobo1.   

Abstract

Estrogen replacement therapy (ERT) has been shown to reduce the risk of cardiovascular disease (CVD) and osteoporosis in postmenopausal women. Studies also indicate a reduced risk of stroke and its consequent mortality among estrogen users, and ERT may also have a role in reducing the risk of Alzheimer's disease and increasing a woman's overall quality of life. On the negative side, some studies show a small duration-related risk of breast cancer with estrogen use and a significant increase in endometrial cancer; the latter is virtually eliminated with the addition of a progestin to the regimen. Although the definitive answer is not yet available, recent epidemiologic data suggest no reduction in protection against CVD and bone fracture with the addition of progestin, which is referred to as hormone replacement therapy, as opposed to using estrogen alone. A woman's potential risks associated with ERT or hormone replacement therapy must be weighed against her lifetime risks of developing CVD, stroke, and bone fracture. The reduction in mortality and morbidity rates with hormone use is generally viewed to be substantial and cost-effective. Health care professionals have an important role in shaping their patients' attitudes. Patients need more information from their physicians about the risks and benefits of estrogen therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573295     DOI: 10.1016/0002-9378(95)90247-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  25 in total

1.  Identification of the novel player deltaEF1 in estrogen transcriptional cascades.

Authors:  E M Chamberlain; M M Sanders
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry.

Authors:  J Embrechts; F Lemière; W Van Dongen; E L Esmans; P Buytaert; E Van Marck; M Kockx; A Makar
Journal:  J Am Soc Mass Spectrom       Date:  2003-05       Impact factor: 3.109

3.  Phytoestrogen alpha-zearalanol inhibits atherogenesis and improves lipid profile in ovariectomized cholesterol-fed rabbits.

Authors:  Shunling Dai; Jinhong Duan; Yuan Lu; Yihua Zhang; Jinxuan Cheng; Jun Ren; Xiaoyuan Zhao; Yunqing Wu; Yue Yu; Pingping Zuo; Yiyong Wu; Qinsheng Ge
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

Review 4.  Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease.

Authors:  N C Inestrosa; M P Marzolo; A B Bonnefont
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

5.  Hormone replacement therapy for all? Universal prescription is desirable.

Authors:  P Toozs-Hobson; L Cardozo
Journal:  BMJ       Date:  1996-08-10

Review 6.  Role of phytoestrogens in cancer therapy.

Authors:  Mandeep K Virk-Baker; Tim R Nagy; Stephen Barnes
Journal:  Planta Med       Date:  2010-07-01       Impact factor: 3.352

7.  A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts.

Authors:  Gaurav Swarnkar; Kunal Sharan; Jawed A Siddiqui; Jay Sharan Mishra; Kainat Khan; Mohd Parvez Khan; Varsha Gupta; Preeti Rawat; Rakesh Maurya; Anil K Dwivedi; Sabyasachi Sanyal; Naibedya Chattopadhyay
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

8.  Phytoestrogen alpha-zearalanol antagonizes oxidized LDL-induced inhibition of nitric oxide production and stimulation of endothelin-1 release in human umbilical vein endothelial cells.

Authors:  Hai-Shan Xu; Jinhong Duan; Shunling Dai; Yunqing Wu; Renyu Sun; Jun Ren
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

9.  Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model.

Authors:  G Mittal; G Chandraiah; P Ramarao; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2008-09-12       Impact factor: 4.200

10.  Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies.

Authors:  H Z Ke; T A Brown; D D Thompson
Journal:  J Am Aging Assoc       Date:  2002-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.